Rosetta Genomics Ltd. (NasdaqCM: ROSG) announced a private placement of 10% senior secured debentures with an accredited investor for gross proceeds of $1,750,000 on January 26, 2012. The debentures have a maturity date of January 26, 2013 and accrue interest at a rate of 10% per annum. An aggregate of $300,000 in principal amount of the debentures may be converted into common shares at a conversion price of $0.0944 per share on the earlier of the date a definitive License Agreement is entered into or February 29, 2012. The securities will be issued pursuant to Regulation D. Aegis Capital Corp. will act as the placement agent and will receive cash compensation in the amount of approximately $96,250 and a warrant to purchase 63,599 shares at an exercise price of $0.1038 per share. On January 27, 2012, Rosetta Genomics Ltd. closed the transaction.